ACTN4 and lung adenocarcinoma: Noro et al. reported that ACTN4 gene amplification was a promising biomarker for predicting the prognosis of chemo-naive patients with stage I adenocarcinoma of the lung, with 5-year DFS and OS rates of patients with ACTN4 gene amplification of 37% and 64%, respectively.